210 related articles for article (PubMed ID: 38350636)
1. Targeting Abnormal Tau Phosphorylation for Alzheimer's Therapeutics.
Singh A; Ansari VA; Mahmood T; Hasan SM; Wasim R; Maheshwari S; Akhtar J; Sheikh S; Vishwakarma VK
Horm Metab Res; 2024 Feb; ():. PubMed ID: 38350636
[TBL] [Abstract][Full Text] [Related]
2. Unlocking hope: GSK-3 inhibitors and Wnt pathway activation in Alzheimer's therapy.
Sai Varshini M; Aishwarya Reddy R; Thaggikuppe Krishnamurthy P
J Drug Target; 2024 Jun; ():1-9. PubMed ID: 38838023
[TBL] [Abstract][Full Text] [Related]
3. The zinc dyshomeostasis hypothesis of Alzheimer's disease.
Craddock TJ; Tuszynski JA; Chopra D; Casey N; Goldstein LE; Hameroff SR; Tanzi RE
PLoS One; 2012; 7(3):e33552. PubMed ID: 22457776
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
5. Delivery of Intravenously Administered Antibodies Targeting Alzheimer's Disease-Relevant Tau Species into the Brain Based on Receptor-Mediated Transcytosis.
Tashima T
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214143
[TBL] [Abstract][Full Text] [Related]
6. Anesthesia and tau pathology.
Whittington RA; Bretteville A; Dickler MF; Planel E
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():147-55. PubMed ID: 23535147
[TBL] [Abstract][Full Text] [Related]
7. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab.
Shi M; Chu F; Zhu F; Zhu J
Front Aging Neurosci; 2022; 14():870517. PubMed ID: 35493943
[TBL] [Abstract][Full Text] [Related]
8. SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer's disease.
Wu X; Kosaraju J; Zhou W; Tam KY
Neuropharmacology; 2018 Mar; 131():351-363. PubMed ID: 29309769
[TBL] [Abstract][Full Text] [Related]
9. Neurobiology of Alzheimer's disease.
Mohandas E; Rajmohan V; Raghunath B
Indian J Psychiatry; 2009 Jan; 51(1):55-61. PubMed ID: 19742193
[TBL] [Abstract][Full Text] [Related]
10. Isoorientin, a GSK-3β inhibitor, rescues synaptic dysfunction, spatial memory deficits and attenuates pathological progression in APP/PS1 model mice.
Tan X; Liang Z; Li Y; Zhi Y; Yi L; Bai S; Forest KH; Nichols RA; Dong Y; Li QX
Behav Brain Res; 2021 Feb; 398():112968. PubMed ID: 33069740
[TBL] [Abstract][Full Text] [Related]
11. GSK-3β and its Inhibitors in Alzheimer's Disease: A Recent Update.
Chauhan N; Paliwal S; Jain S; Verma K; Paliwal S; Sharma S
Mini Rev Med Chem; 2022; 22(22):2881-2895. PubMed ID: 35450523
[TBL] [Abstract][Full Text] [Related]
12. Protein phosphatase 2A dysfunction in Alzheimer's disease.
Sontag JM; Sontag E
Front Mol Neurosci; 2014; 7():16. PubMed ID: 24653673
[TBL] [Abstract][Full Text] [Related]
13. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro S; Valeri A; Mazzon E
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
[TBL] [Abstract][Full Text] [Related]
14. Huannao Yicong decoction ameliorates cognitive deficits in APP/PS1/tau triple transgenic mice by interfering with neurotoxic interaction of Aβ-tau.
Zhang H; Chen W; Li Z; Huang Q; Wen J; Chang S; Pei H; Ma L; Li H
J Ethnopharmacol; 2024 Jan; 318(Pt B):116985. PubMed ID: 37532075
[TBL] [Abstract][Full Text] [Related]
15. Nano-Honokiol ameliorates the cognitive deficits in TgCRND8 mice of Alzheimer's disease via inhibiting neuropathology and modulating gut microbiota.
Qu C; Li QP; Su ZR; Ip SP; Yuan QJ; Xie YL; Xu QQ; Yang W; Huang YF; Xian YF; Lin ZX
J Adv Res; 2022 Jan; 35():231-243. PubMed ID: 35024199
[TBL] [Abstract][Full Text] [Related]
16. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
[TBL] [Abstract][Full Text] [Related]
17. Role of tau protein in Alzheimer's disease: The prime pathological player.
Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B
Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025
[TBL] [Abstract][Full Text] [Related]
18. Cornel Iridoid Glycoside Inhibits Tau Hyperphosphorylation via Regulating Cross-Talk Between GSK-3β and PP2A Signaling.
Yang C; Li X; Gao W; Wang Q; Zhang L; Li Y; Li L; Zhang L
Front Pharmacol; 2018; 9():682. PubMed ID: 29997510
[TBL] [Abstract][Full Text] [Related]
19. Tau and neuroinflammation in Alzheimer's disease: interplay mechanisms and clinical translation.
Chen Y; Yu Y
J Neuroinflammation; 2023 Jul; 20(1):165. PubMed ID: 37452321
[TBL] [Abstract][Full Text] [Related]
20. The neurobiology and therapeutic potential of multi-targeting β-secretase, glycogen synthase kinase 3β and acetylcholinesterase in Alzheimer's disease.
Fronza MG; Alves D; Praticò D; Savegnago L
Ageing Res Rev; 2023 Sep; 90():102033. PubMed ID: 37595640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
